Skip to the main content.
Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

News and Press Releases

Read Veristat news and press releases to learn about our CRO service growth, geographic expansion in Europe and Asia, biotechnology preferred partnerships and small CRO acquisitions.

Posts about

Regulatory Submissions

Veristat congratulates Awakn - UK State Funding to Identify Optimal Pathway to Market In UK & US

Veristat congratulates Awakn for being awarded UK State Funding to Identify Optimal Pathway to...

Veristat Congratulates Origin Biosciences for FDA Approval

Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry during the Week of Rare...

Veristat Supported Marketing Applications for 10% of all FDA Novel Drug Approvals in 2020

Strengthening its Track Record of Successful Client Regulatory Approval Outcomes

SOUTHBOROUGH, MA...

Veristat Announces Global Cell and Gene Therapy Center of Excellence

Accelerating cell and gene therapy opportunities for patients by advancing access to knowledge and...

Veristat Strengthens Its European Presence with the Acquisition of TCTC

Increasing Its Footprint and Expanding Therapeutic Expertise to Guide Sponsors Throughout the...

Veristat Strengthens Its Regulatory Expertise with the Acquisition of Catalyst Regulatory Services

Expanding Its Team of Regulatory Experts to Guide Biopharmaceutical Sponsors Along the Pathway to...

Veristat Supports 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA Approvals

Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding

Veristat Strengthens Clinical Operations Capabilities - Acquires Topstone Research

Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized...

Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™

Continues Collaboration to Provide Regulatory Submission Support for Additional Patisiran...

Veristat Congratulates Agios on the FDA Approval of TIBSOVO®

The First Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and...

Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year

 Veristat’s Continued Innovation of Its Clinical Development Strategies and Services Allow the...